- Home
- OLMA vs CERS Comparison
OLMA vs CERS Comparison
Compare OLMA & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- CERS
- Stock Information
- Founded
- OLMA 2006
- CERS 1991
- Country
- OLMA United States
- CERS United States
- Employees
- OLMA N/A
- CERS N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- CERS EDP Services
- Sector
- OLMA Health Care
- CERS Technology
- Exchange
- OLMA Nasdaq
- CERS Nasdaq
- Market Cap
- OLMA 289.0M
- CERS 347.3M
- IPO Year
- OLMA 2020
- CERS 1997
- Fundamental
- Price
- OLMA $4.67
- CERS $1.36
- Analyst Decision
- OLMA Strong Buy
- CERS Strong Buy
- Analyst Count
- OLMA 3
- CERS 2
- Target Price
- OLMA $27.67
- CERS $3.50
- AVG Volume (30 Days)
- OLMA 902.4K
- CERS 1.1M
- Earning Date
- OLMA 05-16-2025
- CERS 05-01-2025
- Dividend Yield
- OLMA N/A
- CERS N/A
- EPS Growth
- OLMA N/A
- CERS N/A
- EPS
- OLMA N/A
- CERS N/A
- Revenue
- OLMA N/A
- CERS $185,144,000.00
- Revenue This Year
- OLMA N/A
- CERS $25.57
- Revenue Next Year
- OLMA N/A
- CERS $10.54
- P/E Ratio
- OLMA N/A
- CERS N/A
- Revenue Growth
- OLMA N/A
- CERS 13.06
- 52 Week Low
- OLMA $2.86
- CERS $1.12
- 52 Week High
- OLMA $16.62
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- OLMA 50.50
- CERS 50.87
- Support Level
- OLMA $4.35
- CERS $1.22
- Resistance Level
- OLMA $5.74
- CERS $1.38
- Average True Range (ATR)
- OLMA 0.40
- CERS 0.07
- MACD
- OLMA -0.02
- CERS 0.01
- Stochastic Oscillator
- OLMA 25.26
- CERS 53.85
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.